TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note released on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

Shares of NASDAQ:TCON opened at $0.04 on Friday. The company’s fifty day moving average is $0.07 and its two-hundred day moving average is $0.47. TRACON Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.75. The stock has a market capitalization of $148,335.00, a price-to-earnings ratio of 0.01 and a beta of 1.43.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.